Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the acceptance of a late-breaking abstract from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study for a presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023, taking place June 9-11 in Hamburg, Germany, and virtually. NTLA-2002 is an in vivo genome editing candidate designed to inactivate the target gene kallikrein B1 (KLKB1) to permanently reduce plasma kallikrein protein levels and activity and thus prevent hereditary angioedema (HAE) attacks after a single-dose treatment. The presentation will include updated safety and efficacy results from the Phase 1 portion of the study across all three dose cohorts (25 mg, 50 mg and 75 mg).
Title: Updated safety and efficacy of NTLA-2002, a CRISPR/Cas9-based gene editing therapy targeting KLKB1, in a Phase 1 study of patients with hereditary angioedema
Session: Flash talks on immune-mediated diseases
Date and Time: Sunday, June 11, 2023, from 2:30 – 3:30 p.m. CET
Presenter: Remy Petersen, M.D., and Ph.D. candidate, Amsterdam University Medical Center
Intellia Therapeutics Investor Webcast Information
Intellia will host a live webcast on Monday, June 12, 2023, at 8:00 a.m. ET to review the new data. Joining the Intellia management team will be Timothy J. Craig, D.O., tenured professor of Medicine, Pediatrics and Biomedical Sciences at Penn State University, to provide an overview of the current treatment landscape and unmet medical need for people living with HAE.
To join the webcast, please visit this link, or the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for at least 30 days following the call.
About the NTLA-2002 Clinical Program
About Hereditary Angioedema
About Intellia Therapeutics
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; and uncertainties related to the authorization, initiation, enrollment and conduct of studies and other development requirements for its product candidates, including NTLA-2002.. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.